Lauric acid

Lauric Acid (Dodecanoic Acid)

1. Identity and Chemical Characterization

Lauric acid, systematically named dodecanoic acid, is a saturated fatty acid with a 12-carbon atom chain, thus having many properties of medium-chain fatty acids. It was discovered by Marsson T. in 1842 in the seeds of Laurus nobilis, from which it takes its common name. It belongs to the group of saturated fatty acids — there is no double bond in the aliphatic chain, so its shorthand notation in lipid nomenclature is 12:0 — and it is a member of the sub-group called medium-chain fatty acids (MCFA), which encompasses fatty acids containing from 6 to 12 carbon atoms.

Key chemical identifiers:

• Molecular formula: C₁₂H₂₄O₂; molecular weight: 200.32 g/mol; IUPAC name: dodecanoic acid; CAS registry number: 143-07-7; PubChem CID: 3893.
• The salts and esters of lauric acid are known as laurates.
• In purified form it is a white crystalline powder, insoluble in water, with a melting point reported at 44–48 °C and a boiling point of approximately 225 °C at 100 mmHg.

Because lauric acid sits precisely at the 12-carbon boundary, its metabolic behavior is intermediate between classical medium-chain and long-chain fatty acids. Unlike most medium-chain fatty acids, which do not interact strongly with albumin in the blood, lauric acid (C12:0) binds albumin with an affinity nearly equivalent to that of long-chain fatty acids. This partially accounts for its distinctive physiological profile relative to shorter MCFAs such as caprylic (C8) or capric (C10) acid.

2. Natural Sources and Occurrence

Dodecanoic acid (lauric acid) is a straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties, and the main fatty acid in coconut oil and palm kernel oil. As a component of triglycerides, it comprises about half of the fatty-acid content in coconut milk, coconut oil, laurel oil, and palm kernel oil (not to be confused with palm oil). Oils with high levels of lauric acid are collectively known as lauric oils. Outside of these oils, it is relatively uncommon.

The following natural sources contain significant quantities of lauric acid:

• Coconut oil (Cocos nucifera): The primary fatty acid of coconut oil is lauric acid, which is present at approximately 45–53%. Half of the saturated fat content of coconut oil is lauric acid (41.8 grams per 100 grams of total composition), while other significant saturated fats are myristic acid (16.7 g), palmitic acid (8.6 g), and caprylic acid (6.8 g).
• Palm kernel oil (Elaeis guineensis seed): Lauric oils share the main fatty acid lauric acid (12:0), and additionally contain larger amounts of caprylic (8:0), capric (10:0), and myristic (14:0) acids than common seed oils. With the growing production of palm oil, more palm kernels have become available; annual palm kernel oil production is now close to 6 million tons and thus exceeds annual coconut oil production.
• Babassu oil (Attalea speciosa): The palm tree Attalea speciosa, known in Brazil as babassu, contributes approximately 50% lauric acid to babassu oil.
• Human and animal milks: Lauric acid is also found in human breast milk (6.2% of total fat), cow's milk (2.9%), and goat's milk (3.1%).
• Laurel oil (Laurus nobilis): The bay laurel plant, from which the fatty acid was first isolated, also contains lauric acid as a significant component of its seed oil.

3. Common Forms and Preparations

Like many other fatty acids, lauric acid is inexpensive, has a long shelf-life, is nontoxic, and is safe to handle. It is used mainly for the production of soaps and cosmetics; for these purposes, lauric acid is reacted with sodium hydroxide to give sodium laurate, which is a soap.

From a dietary supplement and functional food perspective, lauric acid is encountered in several forms:

• Virgin coconut oil (VCO): Cold-pressed or fermentation-extracted unrefined oil, the most widely consumed whole-food source.
• Refined/fractionated coconut oil: Fractionated coconut oil provides fractions of the whole oil so that its different fatty acids can be separated for specific uses. Lauric acid, a 12-carbon chain fatty acid, is often removed because of its high value for industrial and medical purposes.
• Monolaurin (glycerol monolaurate, GML): Monolaurin — very commonly known by one of its chemical names, glycerol monolaurate (GML) — is the monoester formed from glycerol and lauric acid. Monolaurin first became available as a nutritional formulation in the mid-1960s and today is sold worldwide as a nutritional supplement that is touted as support for immune system function, healthy balance of intestinal flora, and beneficial levels of yeast.
• Purified lauric acid powder: Available as a pharmaceutical- or food-grade white crystalline powder used in research, pharmaceutical formulation, and food manufacturing.
• Sodium lauryl sulfate (SLS): Lauric acid is used in many soaps and shampoos in the form of sodium lauryl sulfate.

4. Traditional and Historical Use

Lauric acid per se was not identified as a discrete chemical entity until 1842. However, the oils richest in lauric acid — particularly coconut oil — have long histories of traditional use across tropical regions.

Coconut oil has a long history in Asia, particularly in tropical regions where the plant is abundant, where it has been used for cooking. It is the oil of choice in Sri Lankan cuisine, where it is used for sautéing and frying, in both savoury and sweet dishes. It also plays a prominent role in the cuisines of Thailand and Kerala.

In the traditional medicine systems of South and Southeast Asia (including Ayurveda in India and folk medicine in the Philippines, Indonesia, and Sri Lanka), coconut oil was applied topically for skin and hair care, used as a base for herbal preparations, and consumed for its perceived antimicrobial and restorative properties. These uses predated any scientific understanding of lauric acid as an active constituent; the health effects attributed to coconut oil in these traditions are now partly understood in terms of its high lauric acid content.

In the context of human lactation, human breast milk is on average 6.2% lauric acid, and breastfeeding provides infants their first introduction to monolaurin. Breastfeeding provides infants with nutrients for growth and development as well as immune protection to compensate for the immature and inexperienced defense mechanisms at mucosal surfaces. The presence of lauric acid and its monoglyceride derivative in breast milk is an evolved nutritional and immunological feature recognized by researchers since the mid-twentieth century, when microbiologists first studied human breast milk for its protective properties against infant pathogens.

5. Key Constituents, Active Metabolites, and Mechanisms of Action

5.1 Lauric Acid as a Precursor to Monolaurin

Some evidence suggests that after ingestion, lauric acid is endogenously converted to monolaurin, which has antiviral, antibacterial, and antifungal effects (Liberman et al., 2006). Monolaurin is glycerol monolaurate: a monoglyceride made from glycerol and lauric acid. Researchers study it because it interacts with lipid membranes, including bacterial membranes and the lipid envelopes around certain viruses.

5.2 Metabolic Pathways and Hepatic Processing

Medium-chain fatty acids (MCFAs) containing 8–12 carbons are absorbed more efficiently than long-chain fatty acids and transported in the portal blood directly to the liver, unlike long-chain fatty acids. Subsequently, MCFAs enter the mitochondria independently of the carnitine transport system and undergo preferential β-oxidation; the resulting glut of acetyl-CoA drives ketone body production, which has been linked to many health benefits.

Coconut oil is rapidly metabolized because it is easily absorbed and lauric acid is easily transported. Detailed studies have shown that the majority of ingested lauric acid is transported directly to the liver where it is directly converted to energy and other metabolites rather than being stored as fat. Such metabolites include ketone bodies, which can be used by extrahepatic tissues, such as the brain and heart, as an immediate form of energy.

A notable exception to the typical MCFA portal-vein transport pathway applies specifically to lauric acid: approximately two-thirds of coconut oil-derived lauric acid is transported via the portal vein, whereas the remainder is carried to the lymph and stored in chylomicrons. This intermediate behavior distinguishes lauric acid from shorter MCFAs (C8, C10), which are transported almost entirely via the portal route.

Acetyl-CoA generated from lauric acid's β-oxidation is converted into ketone bodies such as acetoacetate, β-hydroxybutyrate, and acetone. Additionally, lauric acid is also metabolized by omega-oxidation in a small amount (<10%); cytochrome P450 enzyme is a vital enzyme system involved in fatty acid omega-oxidation. Lauric acid can also be elongated into palmitic acid and myristic acid by extending the carbon chain in the liver.

5.3 Antimicrobial Mechanisms

Three primary mechanisms have been proposed to explain the antimicrobial activity of lauric acid and monolaurin:

1. Membrane disruption: destruction of lipid-coated bacterial and viral cell membranes by physicochemical processes;
2. Signal transduction interference: disturbances of signal transduction and transcription in cells;
3. Host cell membrane stabilization: stabilization of the host-cell membrane (human cells).

The antiviral action, attributed to monolaurin (the monoglyceride of lauric acid), is that of solubilizing the lipids and phospholipids in the envelope of the pathogenic organisms, causing the disintegration of their outer membrane. There is also evidence that MCFAs interfere with the organism's signal transduction, and the antimicrobial effect in viruses is due to interference with virus assembly and viral maturation.

5.4 Lipid-Modifying Effects

Lauric acid (LA; C12:0) has been demonstrated to have the largest cholesterol-raising effect of all fatty acids, raising both low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C). The proposed mechanism by which saturated fatty acids raise LDL-C involves the suppression of hepatic LDL receptor activity: when palmitic, myristic, and lauric acid arrive at the liver, they cannot efficiently feed the acyl-CoA:cholesterol acyltransferase (ACAT) reaction. This causes free cholesterol to accumulate inside liver cells. The buildup suppresses SREBP-2, a transcription factor that controls LDL receptor production. With fewer LDL receptors on liver cell surfaces, less LDL is cleared from the bloodstream, causing blood LDL cholesterol to rise.

6. Scientific Evidence by Area of Use

6.1 Cardiovascular Effects — Lipid Modulation

Evidence strength: Moderate (multiple controlled human trials and a large meta-analysis), though the clinical interpretation of outcomes remains contested.

The effect of lauric acid on serum lipids has been studied in controlled dietary trials and summarized in a landmark meta-analysis.

A pivotal metabolic-diet study in 14 men compared lauric acid directly with palmitic acid and oleic acid: the effects of lauric acid (C12:0) on plasma lipids and lipoproteins were compared with those of palmitic acid (C16:0) and oleic acid (C18:1) using liquid-formula diets fed for 3 weeks each in random order. The high-lauric oil resulted in higher concentrations of plasma total cholesterol (4.94 ± 0.75 mmol/L) and LDL cholesterol (3.70 ± 0.57 mmol/L) compared with high-oleic sunflower oil (4.44 ± 0.54 and 3.31 ± 0.44 mmol/L, respectively), but did not raise total and LDL cholesterol concentrations as much as palm oil. No differences were noted in plasma triglycerides or HDL cholesterol.

A 1995 controlled dietary study concluded that lauric acid raises serum total and LDL cholesterol levels slightly less, and myristic acid raises them more, compared with palmitic acid. Earlier studies had shown that not all saturated fatty acids are equally hypercholesterolaemic: stearic acid (C18:0) and saturated fatty acids with fewer than 12 carbon atoms are not thought to raise serum cholesterol levels, suggesting that the cholesterol-raising effects of saturated fats can be attributed principally to lauric (C12:0), myristic (C14:0), and palmitic (C16:0) acids.

The most comprehensive quantitative synthesis is Mensink et al.'s meta-analysis of 60 controlled dietary trials, which found that although lauric acid raised total cholesterol most among fatty acids relative to carbohydrates, its cholesterol-raising effect was proportionally higher for HDL than for LDL. Consequently, oils rich in lauric acid decreased the ratio of total to HDL cholesterol. The effects of lauric acid-rich fats on coronary artery disease (CAD) risk remain uncertain.

Lauric acid increased HDL cholesterol most significantly, and did so disproportionately relative to total cholesterol, so that its replacement of carbohydrate actually led to a significant decrease in the TC:HDL cholesterol ratio. Despite this, the overall cardiovascular picture is nuanced: replacing dietary coconut oil and its high lauric acid content with oils containing mostly unsaturated fats would alter total blood lipids in a way that reduces cardiovascular disease risk. Epidemiologic studies and randomized clinical trials have provided consistent evidence that replacing saturated fat with polyunsaturated fat, but not carbohydrates, is beneficial for coronary heart disease.

Limitation note: The effects of diet on biomarkers such as blood lipids can never replace studies that employ disease or death as outcomes. No large-scale randomized controlled trial has used lauric acid as an isolated dietary intervention with incident cardiovascular disease as a primary endpoint.

6.2 Antimicrobial Activity — Bacteria, Fungi, and Viruses

Evidence strength: Preclinical evidence is extensive; human clinical evidence is limited.

In vitro and animal studies: Lauric acid and monolaurin have demonstrably significant antimicrobial activity against gram-positive bacteria and a number of fungi and viruses. Lauric acid and monolaurin have a strong ability to destroy gram-positive bacteria, especially S. aureus, fungi such as C. albicans, and viruses including vesicular stomatitis virus (VSV), herpes simplex virus (HSV), and visna virus (VV).

Acne vulgaris (in vitro and murine): A study published in the Journal of Investigative Dermatology (2009) evaluated the antimicrobial potential of lauric acid against the acne-causing bacterium Propionibacterium acnes (now reclassified as Cutibacterium acnes): this study evaluated the antimicrobial property of lauric acid against P. acnes both in vitro and in vivo. Incubation of the skin bacteria P. acnes, Staphylococcus aureus, and Staphylococcus epidermidis with lauric acid yielded minimal inhibitory concentration (MIC) values against bacterial growth over 15 times lower than those of benzoyl peroxide (BPO). The lower MIC values of lauric acid indicate stronger antimicrobial properties than BPO. Both intradermal injection and epicutaneous application of lauric acid effectively decreased the number of P. acnes colonized in mouse ears, thereby relieving P. acnes-induced ear swelling and granulomatous inflammation. These findings are preclinical (in vitro and murine); no completed randomized controlled trials in human acne patients have been published using lauric acid as a standalone intervention.

A further comparative study confirmed that lauric acid had stronger antimicrobial activity against P. acnes than capric acid both in vitro and in vivo. Both fatty acids attenuated P. acnes-induced ear swelling in mice and significantly reduced interleukin (IL)-6 and CXCL8 (IL-8) production in P. acnes-stimulated sebocytes.

Skin infections (in vitro): A cross-sectional laboratory study determined the in vitro sensitivity and resistance of organisms from skin infections and mechanisms of action of monolaurin, a coconut lauric acid derivative, compared with 6 common antibiotics: penicillin, oxacillin, fusidic acid, mupirocin, erythromycin, and vancomycin. Sensitivity rates of Gram-positive Staphylococcus aureus, Streptococcus spp., and coagulase-negative Staphylococcus, and Gram-negative E. vulneris, Enterobacter spp., and Enterococcus spp. to 20 mg/mL monolaurin was 100%, and of Klebsiella rhinoscleromatis was 92.31%. This was an in vitro study only; it does not establish clinical efficacy.

Human clinical evidence — oral supplementation: A systematic review of the clinical literature (PMC, 2020) found that only three peer-reviewed papers evidencing in vivo antimicrobial effects of monolaurin in humans were located, and these were only for intravaginal and intraoral — that is, topical — use. No peer-reviewed evidence was found for the clinical use of monolaurin as a human dietary supplement other than as a nutrient. The underlying research, while still mostly preclinical, is real. This remains the most critical limitation of the antimicrobial evidence base for oral lauric acid/monolaurin supplementation.

6.3 Ketone Body Production and Neurological / Energy Metabolism

Evidence strength: Mechanistic and preclinical; limited direct human data for neurological outcomes specifically attributable to lauric acid.

The medium-chain length provides lauric acid with a competitive advantage over long-chain fatty acids in its metabolism; MCFAs enter the liver via the hepatic portal vein and are utilized into energy and energy metabolites like ketone bodies via a carnitine-independent pathway in mitochondria, rather than being stored in adipose tissues. Detailed studies have shown that the majority of ingested lauric acid is transported directly to the liver where it is directly converted to energy and other metabolites rather than being stored as fat. Such metabolites include ketone bodies, which can be used by extrahepatic tissues, such as the brain and heart, as an immediate form of energy.

MCFAs are unique in that they are easily absorbed and metabolised by the liver, and can be converted to ketones. Ketone bodies are an important alternative energy source in the brain, and may be beneficial to people developing or already with memory impairment, as in Alzheimer's disease (AD). Research directly attributing these neurological benefits to lauric acid specifically rather than to medium-chain triglycerides collectively (C8 and C10, which are the main components of MCT oil) remains limited.

6.4 Anti-inflammatory Properties

Evidence strength: Mostly in vitro and animal models; human data lacking.

Studies examining lauric acid's anti-inflammatory potential have been conducted primarily in cell culture and animal models. An in silico study suggested that lauric acid's interaction with specific protein targets of C. acnes may contribute to its synergistic antibacterial and anti-inflammatory effects. A 2014 study comparing capric and lauric acids showed that both fatty acids reduced pro-inflammatory cytokines in sebocyte cell lines and attenuated ear inflammation in mice, with lauric acid demonstrating stronger antimicrobial activity against P. acnes than capric acid both in vitro and in vivo. These results have not yet been translated into controlled clinical trials.

6.5 Eryptosis and Hematological Effects

Evidence strength: Novel in vitro finding; clinical relevance unclear.

A 2021 study published in Cells (MDPI) reported a previously undescribed effect of lauric acid on red blood cells: lauric acid caused dose-responsive hemolysis, and calcium-dependent phosphatidylserine (PS) exposure, elevated erythrocyte sedimentation rate (ESR), cytosolic calcium overload, cell shrinkage and granularity, oxidative stress, accumulation of lipid peroxides, and stimulation of casein kinase 1α (CK1α). In whole blood, lauric acid disrupted leukocyte distribution with elevated neutrophil-lymphocyte ratio (NLR) due to selective toxicity to lymphocytes. These were in vitro experiments exposing isolated red blood cells to 50–250 μM of lauric acid for 24 hours; the physiological relevance of these concentrations to dietary exposure has not been established.

7. Body Systems and Health Areas Associated with Lauric Acid

• Cardiovascular system: Influences total cholesterol, LDL-C, and HDL-C levels; the net effect on cardiovascular risk is debated because it raises both LDL and HDL. Lauric acid increases total cholesterol levels and leads to improvements in the total cholesterol to HDL-C ratio, which is important for estimating CVD risk.
• Immune system / antimicrobial defense: Dodecanoic acid has a role as an antibacterial agent, a plant metabolite, and an algal metabolite. Its conversion to monolaurin is thought to contribute to the antimicrobial activity of breast milk.
• Integumentary system (skin): Investigated for topical antibacterial activity against acne-causing bacteria, and for use as an emollient and skin barrier constituent in personal care products.
• Energy metabolism / hepatic function: Primarily metabolized in the liver via β-oxidation; generates ketone bodies usable by brain and cardiac muscle.
• Hematological system: In vitro evidence of pro-eryptotic (red blood cell death) activity at supraphysiological concentrations; in vivo significance unknown.
• Gastrointestinal system: The gut microbiota may influence or be influenced by lauric acid's metabolism; the fate of lipids in vivo is also closely related to gut microbiota, and healthy gut microbiota is required for efficient absorption of dietary lipids for normal absorption, storage, and secretion.

8. Dosage Forms and Dosages Reported in Studies

There is no established dietary reference intake (DRI) or recommended daily allowance (RDA) for lauric acid as an isolated supplement. Dosages used in research contexts include:

• Controlled dietary trials (lipid effects): In a metabolic-diet study of 14 men, liquid-formula diets providing lauric acid (via a synthetic high-lauric oil), palmitic acid (from palm oil), or oleic acid (from oleic-rich sunflower seed oil) were each fed for 3 weeks in random order. The study measured the effect at levels approximating typical dietary fat intake rather than a specific supplemental dose.
• Monolaurin (oral supplement): Monolaurin has FDA GRAS (Generally Recognized as Safe) status for food use and a reassuring safety profile, especially at food-additive exposure levels. The important limit is that high-dose oral supplement use has not been tested in large, long-term human trials.
• Acute oral toxicity study (animal): Conducted in accordance with OECD guidelines (OECD 423), lauric acid was administered orally to female Sprague-Dawley rats at single doses of 300 and 2,000 mg/kg body weight; animals from all groups were monitored for any behavioral and toxicological changes and mortality for two weeks.
• Dairy cow supplementation: Forty primiparous Holstein dairy cows were divided into four groups; four treatments included a control (0 g/day) and low-LA (100 g/day), medium-LA (200 g/day), and high-LA (300 g/day) per cow. (Note: this is a veterinary study and doses are not applicable to humans.)
• Breast milk lauric acid augmentation: Eating 40 grams (about 3 tablespoons) of coconut oil has been shown to increase lauric acid in the milk of a nursing mother from 3.9% to 9.6% after 14 hours.

No official pharmacopeial monograph (USP, European Pharmacopoeia, WHO) establishing a supplemental dose range for lauric acid as an isolated compound in humans has been published.

9. Safety Considerations

9.1 General Safety Status

Lauric acid is safe for use in food products according to the FDA (§172.860, 2000). Monolaurin, a derivative of lauric acid, is included on the FDA's Generally Recognized as Safe (GRAS) list and is widely used in food manufacturing. The reported oral LD₅₀ in rats is 12 g/kg.

9.2 Genotoxicity and Repeated-Dose Toxicity

Lauric acid was evaluated for genotoxicity, repeated-dose toxicity, reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, and environmental safety. Data show that lauric acid is not expected to be genotoxic. Data on a read-across analog provide a calculated margin of exposure (MOE) >100 for the repeated-dose toxicity and reproductive toxicity endpoints. Based on the existing data, lauric acid does not present a concern for skin sensitization under current declared levels of use.

9.3 Cardiovascular Lipid Risk

Saturated fatty acids contribute to cardiovascular disease by aggravating dyslipidemia, and, in particular, lauric acid raises circulating cholesterol levels. The cholesterol-raising effects of dietary saturated fatty acids are attributable principally to lauric acid (C12:0), myristic acid (C14:0), and palmitic acid (C16:0). While lauric acid's favorable effect on the total cholesterol:HDL ratio has been cited as a possible mitigating factor, replacing dietary coconut oil and its high lauric acid content with oils containing mostly unsaturated fats would alter total blood lipids in a way that reduces cardiovascular disease risk.

9.4 Pro-eryptotic Effects (In Vitro)

A 2021 study provides the first evidence of the pro-eryptotic potential of lauric acid and its associated mechanism. At concentrations of 50–250 μM in isolated red blood cells over 24 hours, lauric acid caused dose-responsive hemolysis, calcium-dependent phosphatidylserine exposure, elevated erythrocyte sedimentation rate, cytosolic calcium overload, cell shrinkage and granularity, oxidative stress, and accumulation of lipid peroxides. The in vivo and clinical relevance of this finding for dietary lauric acid intake remains to be established; the concentrations studied are pharmacological rather than physiological.

9.5 Skin Sensitization and Comedogenicity

Lauric acid is a mild irritant but not a sensitizer, and some sources cite it as comedogenic. The comedogenicity concern — the potential to clog pores when applied topically — is recognized in dermatological literature, though its magnitude at cosmetically relevant concentrations is debated.

9.6 Pregnancy and Lactation

Lauric acid is a normal constituent of human breast milk and of many dietary oils consumed by pregnant and breastfeeding women. Additional studies are required to fully understand the impact, efficacy, and safety of utilizing coconut oil or monolaurin during breastfeeding of infants.

9.7 Interactions

No well-documented drug–nutrient interactions specific to lauric acid as an isolated supplement have been established in peer-reviewed clinical literature. Because lauric acid undergoes hepatic metabolism involving cytochrome P450 enzymes — specifically, lauric acid is metabolized by omega-oxidation in a small amount (<10%), with cytochrome P450 enzyme being a vital enzyme system involved in fatty acid omega-oxidation, and it was proved to catalyze the hydroxylation of lauric acid in hepatocytes — theoretical interactions with drugs that are potent CYP enzyme inhibitors or inducers cannot be excluded, but this has not been characterized in human pharmacological studies.

---

References

• PubChem — Lauric Acid (CID 3893), National Library of Medicine
• The Clinical Use of Monolaurin as a Dietary Supplement: A Review of the Literature — PMC / Alternative Therapies in Health and Medicine (2020)
• Dayrit FM. The Properties of Lauric Acid and Their Significance in Coconut Oil. Journal of the American Oil Chemists' Society, 2015.
• Siri-Tarino PW et al. Saturated Fatty Acids and Risk of Coronary Heart Disease: Modulation by Replacement Nutrients. Current Atherosclerosis Reports, 2010 — PMC
• Mensink RP et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. American Journal of Clinical Nutrition, 2003.
• Al-Suhaimi EA et al. Lauric Acid, a Dietary Saturated Medium-Chain Fatty Acid, Elicits Calcium-Dependent Eryptosis. Cells, 2021 — PMC
• Nakatsuji T et al. Antimicrobial Property of Lauric Acid Against Propionibacterium acnes: Its Therapeutic Potential for Inflammatory Acne Vulgaris. Journal of Investigative Dermatology, 2009 — PMC
• Carpo BG et al. Novel antibacterial activity of monolaurin compared with conventional antibiotics against organisms from skin infections: an in vitro study. Journal of Drugs in Dermatology, 2007 — PubMed
• Temme EH et al. Comparison of effects of lauric acid and palmitic acid on plasma lipids and lipoproteins. American Journal of Clinical Nutrition, 1992 — PubMed
• Zock PL, Katan MB. Dietary saturated and trans fatty acids and lipoprotein metabolism. Current Opinion in Lipidology, 1994 — PubMed
• Huang WC et al. Anti-bacterial and anti-inflammatory properties of capric acid against Propionibacterium acnes: a comparative study with lauric acid. Journal of Dermatological Science, 2014 — PubMed
• Lauric acid — Wikipedia (with cited primary sources)
• Lauric Acid — ScienceDirect Topics Overview
• Sugiyama H et al. Metabolism and pharmacokinetics of medium chain fatty acids after oral administration of royal jelly to healthy subjects. RSC Advances, 2019.
• Omar NA et al. Food additive "lauric acid" possess non-toxic profile on biochemical, haematological and histopathological studies in female Sprague Dawley (SD) rats — PMC, 2020
• RIFM Fragrance Ingredient Safety Assessment — Lauric Acid (CAS 143-07-7)
• Ye J et al. Influences of lauric acid addition on performance, nutrient digestibility and proteins related to mammary gland development in dairy cows — PMC, 2024